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CON S E N S U S S T A T EM EN T
Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date infor-
mation on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection
of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the
process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such
evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership that may be
incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited before publication. The
authors are solely responsible for the content of the statements.
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Abstract
Cardiomyopathies are a heterogeneous group of myocardial disorders of mostly
unknown etiology, and they occur commonly in cats. In some cats, they are well-
tolerated and are associated with normal life expectancy, but in other cats they
can result in congestive heart failure, arterial thromboembolism or sudden death.
Cardiomyopathy classification in cats can be challenging, and in this consensus
statement we outline a classification system based on cardiac structure and func-
tion (phenotype). We also introduce a staging system for cardiomyopathy that
includes subdivision of cats with subclinical cardiomyopathy into those at low risk
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of life-threatening complications and those at higher risk. Based on the available
literature, we offer recommendations for the approach to diagnosis and staging of
cardiomyopathies, as well as for management at each stage.
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1 | INTRODUCTION
Cardiomyopathies are a heterogeneous group of myocardial diseases
with variable phenotype and prognosis. Cardiomyopathies are com-
mon in cats, and cardiovascular disease is among the 10 most com-
mon causes of death in cats.1-3 The following report by the American
College of Veterinary Internal Medicine consensus statement panel
on cardiomyopathy in cats proposes an updated classification of car-
diomyopathies based on echocardiographic phenotype, and provides
recommendations for the diagnostic approach and management of
cats with myocardial disease.
2 | CONSENSUS METHODS
A modified Delphi method was applied to a series of statements
produced by members of the committee that summarized the most
important issues related to cardiomyopathy in cats. A combination
of online anonymous voting with free text comments, face-to-face
meetings and video-conferences was used to modify the state-
ments. Consensus was defined as ≧6 of the 9 committee members
agreeing with a statement. A PubMed search using the MeSH terms
“feline” and “cardiomyopathies” yielded 475 references, and further
references were identified using other databases and other search
terms. References documenting peer-reviewed published studies
containing original data were reviewed by the panel and graded. For
each statement for which consensus was reached, a level of evidence
(low/medium/high), was determined based on review of the literature
(Table 1), and a class (strength) of recommendation was assigned
(is recommended/should be considered/may be considered/is not rec-
ommended) according to the results of voting (Table 2).
3 | DEFINITIONS AND CLASSIFICATION
OF CARDIOMYOPATHIES IN CATS
Cardiomyopathy is defined as a myocardial disorder in which the
heart muscle is structurally and functionally abnormal in the
absence of any other cardiovascular disease sufficient to cause the
observed myocardial abnormality.4 Classification of cardiomyopa-
thies in cats previously has been based on schemes that were
applied to cardiomyopathy in humans, but currently several
competing classification systems are used in humans, highlighting
the difficulties inherent in cardiomyopathy classification.4-7 The
aim of disease classification is to categorize conditions according to
logical principles, such as by organ involvement, pathophysiology,
phenotype, or underlying cause. An ideal classification system
would standardize terminology and facilitate clinical management,
but all classification systems have limitations, and this is particularly
true when the underlying causes of disease are unknown. In
humans, the cause of cardiomyopathy often can be determined, but
this is rarely true in cats. We propose an adaptation of the
European Society of Cardiology (ESC) classification4 for use in cats,
because this scheme is based on phenotypic features without
assumptions regarding underlying cause, and it focuses on a clinical,
rather than genetic, approach to these disorders (Figure 1, Table 3).
TABLE 1 Levels of evidence
Levels of evidence
High Randomized controlled trials in cats
Prospective, nonrandomized controlled
trials in cats, with adequate sample size
and lacking major methodological flaws
Medium Experimental laboratory trials in cats
Retrospective clinical studies with
intervention & control groups
Low Case series in cats without control groups
Studies in other species
Expert opinion
TABLE 2 Class of recommendations
Class of recommendations
Evidence/agreement that intervention
is beneficial/useful/effective (Class I)
“is recommended/indicated”
Evidence/opinion in favor of
usefulness/efficacy (Class IIa)
“should be considered”
Evidence/opinion less
well established (Class IIb)
“may be considered”
Evidence/agreement that
intervention is not useful/effective
and in some instances may
be harmful (Class III)
“is not recommended”
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The ESC classification is based on the traditional phenotypic cate-
gories of hypertrophic cardiomyopathy (HCM), restrictive cardio-
myopathy (RCM), dilated cardiomyopathy (DCM), unclassified
cardiomyopathy (UCM), and arrhythmogenic right ventricular car-
diomyopathy (ARVC), and we recommend retaining these catego-
ries (with the exception of UCM) as a basic framework, while
acknowledging their limitations. For example, in some cats, the car-
diac phenotype changes over time, because of disease progression,
comorbidities or unknown factors.
We propose a classification of cardiomyopathies in cats based on
structural and functional characteristics, or phenotype. The phenotypic cat-
egories include catswith cardiomyopathy of both known causes (eg, hyper-
thyroidism, sarcomeric gene mutation) and unknown causes (most cats
with a cardiomyopathy phenotype). Until an underlying cause is sought, a
cat is said to have a “hypertrophic cardiomyopathy phenotype” or a “dilated
cardiomyopathy phenotype” (according to the cardiac morphology and
function). If no underlying cause is found, a cat is said to have “hypertrophic
cardiomyopathy (HCM)” or “dilated cardiomyopathy (DCM),” as appropri-
ate. The proposed classification therefore does not define specific disease
entities, but phenotypic categories instead. The description in any individ-
ual cat can be further refined by details of cause when known. Thus, a cat
with left ventricular (LV) hypertrophy and hyperthyroidism is said to have
anHCMphenotype in conjunctionwith hyperthyroidism.
Some cats have myocardial disease that does not fit well into any
category. Rather than describe these cases as having “unclassified
cardiomyopathy,” according to the proposed classification these cats
should be described as having cardiomyopathy with a “nonspecific phe-
notype.” This term always should be accompanied by a description of
F IGURE 1 Classification of cardiomyopathy phenotypes. (adapted with permission from Clinical Small Animal Internal Medicine, Ed David
Bruyette, John Wiley & Son). ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; End-stage HCM, HCM
with systolic dysfunction; HCM, hypertrophic cardiomyopathy; RCM, restrictive cardiomyopathy; TMT, transient myocardial thickening
TABLE 3 Definitions of cardiomyopathy phenotypes. Cardiomyopathy is defined as a myocardial disorder in which the heart muscle is
structurally and functionally abnormal in the absence of any other disease sufficient to cause the observed myocardial abnormality
Phenotype Definition
Hypertrophic cardiomyopathy (HCM) Diffuse or regional increased LV wall thickness with a nondilated LV chamber.
Restrictive cardiomyopathy (RCM)
Endomyocardial form Characterized macroscopically by prominent endocardial scar that usually bridges the
interventricular septum and LV free wall, and may cause fixed, mid-LV obstruction and
often apical LV thinning or aneurysm; LA or biatrial enlargement is generally present.
Myocardial form Normal LV dimensions (including wall thickness) with LA or biatrial enlargement
Dilated cardiomyopathy (DCM) LV systolic dysfunction characterized by progressive increase in ventricular dimensions,
normal or reduced LV wall thickness, and atrial dilatation.
Arrhythmogenic cardiomyopathy (AC), also known as
arrhythmogenic right ventricular cardiomyopathy
(ARVC) or dysplasia (ARVD)
Severe RA and RV dilatation and often, RV systolic dysfunction and RV wall thinning. The
left heart may also be affected. Arrhythmias and right-sided congestive heart failure are
common.
Nonspecific phenotype A cardiomyopathic phenotype that is not adequately described by the other categories;
the cardiac morphology and function should be described in detail
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the morphologic and functional features to characterize the phenotype
in more detail.
3.1 | Staging cardiomyopathies in cats
For describing the clinical impact of cardiomyopathy in affected
cats, we propose a staging system adapted from the American
Heart Association (AHA) and American College of Veterinary
Internal Medicine (ACVIM) heart disease staging systems8-10
(Figure 2), with the aim of providing a framework for prognostica-
tion and therapeutic decision-making. Stage A includes cats that
are predisposed to cardiomyopathy but have no evidence of myo-
cardial disease. Stage B describes cats with cardiomyopathy but
without clinical signs. Stage B is further divided into stage B1:
cats at low risk of imminent congestive heart failure (CHF) or
arterial thromboembolism (ATE), and stage B2: cats at higher risk
of imminent CHF or ATE. Atrial size is an important prognostic
marker, and it can be used as a means of subdividing cats with
subclinical cardiomyopathy into low risk (B1) and higher risk
(B2) cats. The more severe the left atrial (LA) enlargement, the
higher the risk of CHF and ATE.11 Other factors also should be
taken into consideration when staging cats with subclinical car-
diomyopathy, such as LA and LV systolic function, and extreme
LV hypertrophy, among others (see Figure 2). Cats that have
developed signs of CHF or ATE are classified as stage C, even if
clinical signs resolve with treatment. Cats with signs of CHF
refractory to treatment are classified as stage D.
4 | PREVALENCE AND NATURAL HISTORY
The most common type of cardiomyopathic phenotype is HCM and
thus it is the major focus in these guidelines, but other phenotypes will
be addressed separately where appropriate. Hypertrophic cardiomyopa-
thy has an estimated prevalence of approximately 15% in the general
cat population.12-16 In older cats, the prevalence is much higher, with
up to 29% reported affected, even when cats with hypertension and
hyperthyroidism are excluded.15 Most cats with HCM have subclinical
disease, with a 5-year cumulative incidence of cardiac mortality of
approximately 23%, independent of age at diagnosis.17 Congestive
heart failure (CHF) is the most common cause of clinical signs in
cats with HCM, followed by arterial thromboembolism (ATE).17 A
minority of cats die suddenly without prior clinical signs.11,17,18 The
prevalence of other cardiomyopathy phenotypes in the general cat
population is not known, but a hypertrophic phenotype appears to
predominate in cats with subclinical cardiomyopathy.15
Compared with normal cats, cats with HCM are more likely to be
older, male, and have a loud systolic murmur, although HCM still can
be seen in young cats, females, and in cats without a murmur.15,19-22
Most cats with HCM are nonpedigree, but some pedigree breeds are
believed to be at increased risk, including Maine Coon, Ragdoll, British
Shorthair, Persian, Bengal, Sphynx, Norwegian Forest cat, and Birman
breeds.20,23-27 However, comprehensive prevalence data are lacking
for pedigree cats. Sarcomeric gene mutations are common in people
with HCM, but only 2 mutations have been identified in cats, both in
the myosin binding protein C (MyBPC3) gene.23,28 The estimated
prevalence of the MyBPC3-A31P mutation in Maine Coon cats is
approximately 35% to 42%,29,30 which is substantially higher than the
prevalence of the HCM phenotype in this breed.30 Maine Coon cats
that are homozygous for this mutation, Ragdolls homozygous for the
MyBPC3-R820W mutation, and first-degree relatives of affected cats
are at higher risk of developing HCM.30-33 The role of nongenetic and
epigenetic factors in HCM in cats is unknown, although such factors
might be important in humans with HCM.34
4.1 | Prognosis
Some cats with an HCM phenotype remain subclinical, whereas others
develop CHF or ATE.13,17,19-21,32,35-37 Younger age22 and lack of clinical
signs19,20,22,35 have been associated with longer survival. Markers of
increased risk of CHF or ATE include presence of a gallop sound or
arrhythmia on physical examination, moderate to severe LA enlargement,
decreased LA fractional shortening (LA FS%), extreme LV hypertrophy,
decreased LV systolic function, spontaneous echo-contrast or intracardiac
thrombus, regional wall thinning with hypokinesis, and a restrictive dia-
stolic filling pattern.11,22,38 Sudden cardiac death also occurs in cats with
F IGURE 2 Stages of feline cardiomyopathy. Within stage B2, additional risk factors include a gallop sound, arrhythmia, decreased left atrial
function, extreme left ventricular hypertrophy, left ventricular systolic dysfunction, spontaneous echo-contrast/thrombus, regional wall motion
abnormalities. ATE, arterial thromboembolism; CHF, congestive heart failure
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HCM.17,18,21 Less is known about risk factors for sudden cardiac death,
but these might include a history of syncope, ventricular arrhythmias, LA
enlargement, and regional LV wall hypokinesis.11 Median survival times
are substantially shorter in cats with HCM that develop CHF or ATE com-
pared to those with subclinical cardiomyopathy.17,19-22,35 Cats that
develop CHF associated with stress, IV fluid therapy, general anesthesia,
or extended-release corticosteroid treatment might have longer survival
times compared with cats that develop CHF in the absence of these fac-
tors.3,17,39 Factors associated with longer survival times after treatment
for CHF include a greater decrease in NT-proBNP concentrations during
hospitalization and resolution of CHF at reexamination.40
In contrast to HCM in people, in whom dynamic left ventricular out-
flow tract obstruction (DLVOTO) has been associated with increased
morbidity and mortality,41 DLVOTO does not appear to be a poor prog-
nostic factor in cats.17,21,22 This might be a true difference between
HCM in humans and cats, but also could reflect differences in how
DLVOTO is defined between species, or the result of bias in retrospec-
tive studies (cats with DLVOTO are more likely to be investigated for an
incidentally detected murmur than cats with nonobstructive HCM, which
often are not diagnosed until clinical signs develop).
5 | DIAGNOSIS
Establishing the diagnosis of cardiomyopathy in cats can be challeng-
ing, particularly in general practice. Echocardiography performed by a
veterinary cardiology specialist is the diagnostic test of choice, but dif-
ferentiation of the various phenotypic categories sometimes can be
challenging, even for specialists. Fortunately, with regard to therapeu-
tic decision-making, the requirement for diuretics in cats with CHF
and the approach to management of ATE are similar regardless of the
form of cardiomyopathy. A basic level of echocardiographic skill (eg,
ability to detect moderate to severe left atrial enlargement) can be
sufficient to identify the more advanced stages of cardiomyopa-
thy.42,43 Other diagnostic tests may facilitate disease staging, identifi-
cation of important comorbidities and establishing prognosis.
Importantly, tests are recommended to screen for a possible underly-
ing cause for the cardiomyopathy phenotype, such as serum thyroxine
concentration for hyperthyroidism or blood pressure measurement
for systemic hypertension in cats with an HCM phenotype.
5.1 | Genetic testing
Genetic testing for the MyBPC3-A31P mutation and the MyBPC3
R820W mutation is recommended in Maine Coon and Ragdoll cats
(respectively) intended for breeding (level of evidence [LOE] high),
with the aim of decreasing the incidence of these mutations and HCM
in these breeds.29,30,44 It is recommended that cats homozygous for
either mutation not be used for breeding, but heterozygous cats can
be bred to genotype-negative cats if they have other outstanding
characteristics (LOE low). The same genetic tests can be considered in
nonbreeding Maine Coon or Ragdoll cats to determine the relative risk
of developing HCM (LOE medium). In Maine Coon cats it is primarily
individuals that are homozygous for the A31P mutation that develop
clinically relevant HCM.44 Maine Coon and Ragdoll cats that test neg-
ative for these MYBPC3 mutations have been reported with HCM
(LOE high),44,45 and thus regular echocardiographic screening should
be considered even in Maine Coon and Ragdoll cats without these
mutations (LOE low). Genetic testing for the A31P and R820W
MYBPC3 mutations in non-Maine Coon or non-Ragdoll cats is not
recommended, because these 2 mutations are almost completely spe-
cific to Maine Coon and Ragdoll cats (LOE high).29,30
5.2 | History
The history is unremarkable in many cats with cardiomyopathy, partic-
ularly those with HCM. The most common presenting sign is labored
breathing,17 although some cats only show nonspecific signs such as
hiding or inappetence. Congestive heart failure appears to be the
most common cause of respiratory distress in cats.46,47 Paresis or
paralysis associated with ATE is also a common presenting sign,17
with syncope being less common.19 In some cats with cardiomyopa-
thy, sudden death may occur with no premonitory signs.18
5.3 | Physical examination
5.3.1 | Subclinical cardiomyopathy
A parasternal systolic heart murmur has been reported in up to 80% of
cats with subclinical HCM, compared with 30%-45% of healthy cats
without HCM.14-17 Third heart sounds such as gallop sounds have been
reported in 2.6%-19% of cats with subclinical HCM and are seldom pre-
sent in healthy cats.15 Arrhythmias also can be associated with cardiomy-
opathies.48,49 Many affected cats have no auscultatory abnormality.15,42
Further investigations are recommended if a heart murmur is detected in
any cat (LOE medium).15,42 A loud systolic murmur (grade 3-4/6) is more
common in cats with HCM than in normal cats, but an increase in heart
murmur intensity over time does not necessarily indicate the presence or
worsening of disease. A palpable thrill (grade 5-6/6 murmur) seldom is
associated with cardiomyopathy in cats and is more likely to be associ-
ated with a congenital malformation. Cats with more advanced disease
(or those with restrictive or dilated phenotypes) may not have an audible
murmur.13,21,42,50 Auscultation of a gallop sound or an arrhythmia is more
likely to be associated with cardiomyopathy, although differentiation of a
gallop sound from other third heart sounds or a bigeminal rhythm can be
challenging.
5.3.2 | Cardiomyopathy associated with CHF
Tachypnea, labored breathing or both are the typical historical and
physical examination findings in cats with left heart failure. Compared
with cats that have subclinical HCM, a gallop sound or an audible
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arrhythmia are more common in cats with CHF, and murmurs are
less common.13,21,43 In one study, cats presented to first opinion prac-
tices for evaluation of respiratory distress with respiratory rates
>80 breaths/min, gallop sounds, rectal temperatures <37.5C or heart
rates >200 bpm were more likely to have CHF than other causes of
dyspnea.47 Pulmonary crackles can be heard when pulmonary edema
is present, and breath sounds are often diminished ventrally when
pleural effusion is present, together with paradoxical breathing.51
5.4 | Radiography
Cardiomyopathy might be suspected when severe cardiomegaly is pre-
sent radiographically, when a left auricular bulge is present on dorso-
ventral/ventrodorsal radiographic views, or both.52,53 Thoracic
radiography is insensitive for identification of mild or moderate cardiac
changes associated with cardiomyopathy, and in some cats the cardiac
silhouette may appear normal even when disease is severe enough to
cause CHF.54 Furthermore, it is difficult to identify the cardiomyopathy
phenotype from the shape of the cardiac silhouette, and the classic “val-
entine-shaped” heart is not specific for HCM, as previously thought.55,56
Although radiography is considered the gold standard for confirming
the presence of cardiogenic pulmonary edema, if radiographs cannot be
obtained safely consideration should be given to delaying thoracic radi-
ography (LOE low). In contrast to dogs, the radiographic pattern associ-
ated with cardiogenic pulmonary edema in cats is highly variable.52,57 A
combination of physical examination, point-of-care ultrasound examina-
tion and point-of-care NT-proBNP often can be helpful when deciding
if CHF is the cause of respiratory distress (LOE high).58
5.5 | Cardiac biomarkers
5.5.1 | NT-proBNP
The quantitative feline-specific NT-proBNP assay using plasma or
pleural fluid has good diagnostic accuracy for discriminating between
cats with cardiac and noncardiac causes of respiratory distress (LOE
high),59-64 but it is not recommended for guiding therapeutic decision-
making in cats with respiratory distress because of the delay in receiv-
ing test results from an external laboratory. Instead, a point-of-care
NT-proBNP assay provides rapid results while maintaining reasonable
diagnostic accuracy in discriminating between cardiac and noncardiac
causes of respiratory distress, and should be considered when point-
of-care ultrasound examination is not available (LOE medium).58,65
The point-of-care assay can be used on plasma or pleural fluid,64,66
the latter diluted 1:1 with saline for greater specificity.65
When investigating a cat suspected to have subclinical cardiomyopa-
thy there is less urgency for test results, and so the quantitative NT-
proBNP assay can be considered in situations where echocardiography is
not available (LOE high). The quantitative NT-proBNP assay is not rec-
ommended for differentiating normal cats from cats with mild to moder-
ate HCM (LOE high).67-69 The point-of-care assay can be considered in
cats with suspected subclinical cardiomyopathy, but its principal value is
in differentiating cats with severe subclinical cardiomyopathy from nor-
mal cats or cats with only mild disease (LOE high).70,71
5.5.2 | Troponin-I
Measuring circulating cardiac troponin-I (cTnI) concentrations can help
discriminate between cardiac and noncardiac causes of respiratory
distress (LOE medium), but only when results can be obtained rap-
idly.72-74 High-sensitivity assays for human cTnI might be considered
for differentiating between normal cats and cats with subclinical HCM
when cardiac disease is suspected (LOE medium).75,76 In addition, cTnI
also might be considered for its prognostic value, because an
increased circulating cTnI concentration is associated with increased
risk of cardiovascular death independent of LA size (LOE high).77
5.6 | Electrocardiography
The sensitivity of a 6-lead ECG for detecting LV hypertrophy or LA
enlargement is low,13,78,79 and ECG is not recommended as a screening
method for cardiomyopathies in cats (LOE medium), despite its use in
screening people for HCM.80 Nevertheless, a variety of arrhythmias can
occur in cats with cardiomyopathy,48,49,78,81-85 and can contribute to
clinical signs such as weakness, syncope, and hypoxic-anoxic sei-
zures.86,87 Although ambulatory (Holter) ECG monitoring is tolerated less
well by cats than dogs, it can identify arrhythmias that might otherwise
go undetected.49,88 It is recommended that cats experiencing episodic
weakness and collapse (including seizure-like activity) should undergo a
cardiovascular evaluation that includes echocardiography, ECG, and tele-
metric or Holter ECG monitoring if necessary. Implantable loop recorders
also should be considered for cats with intermittent clinical signs that
could be attributed to arrhythmias89,90 (LOE low). Other options for
recording cardiac rhythm in the cat's home environment include use of a
portable electrode plate (Kardia AliveCor) in conjunction with a
smartphone to record an ECG that can be interpreted by a specialist.
5.7 | Blood pressure
Diffuse or segmental LV hypertrophy is common in cats with systemic
hypertension and is observed in up to 85% of cases, although HCM
and systemic hypertension may exist concurrently. For many hyper-
tensive cats, LV hypertrophy is only mild to moderate.91-94 Blood
pressure determination should be considered for all cats with
increased LV wall thickness (LOE medium).
5.8 | Thyroxine measurement
Hyperthyroidism is common in older cats, and is associated with auscul-
tatory abnormalities (murmur, gallop, arrhythmias), cardiac remodeling
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(LV hypertrophy or increased cardiac chamber diameters), and in some
cases, CHF or ATE.95-98 Hyperthyroid cats with severe LV hypertrophy
are sometimes seen, but this association is suspected to be the result of
hyperthyroidism exacerbating preexisting mild to moderate HCM (LOE
low). It is recommended that serum thyroxine concentrations be mea-
sured in all cats ≧6 years of age with abnormal cardiac auscultation find-
ings with or without LV hypertrophy on an echocardiogram (LOE low).
5.9 | Echocardiography
Echocardiography is the gold standard test for diagnosis of cardiomyopa-
thies in cats. Indications for echocardiography are listed in Table 4. Echo-
cardiography ideally should be performed by trained operators99 in
unsedated cats in quiet conditions, and cats should be handled with mini-
mal restraint. When necessary, sedation of the cat may be considered
for echocardiographic examination.100 Adequate echocardiographic
images can be obtained whether the cat is in lateral recumbency or
standing.99
Measurements of LV wall thickness traditionally have been made
from 2D-guided M-mode echocardiographic images, although this
mode is limited to focal sampling of the LV. Because of regional het-
erogeneity of LV hypertrophy in many cats with HCM, measurements
using M-mode echocardiography can miss focal wall thickening. Inad-
vertent measurement of papillary muscles also is possible as a result
of translational motion of the heart. Two-dimensional echocardiogra-
phy allows measurement of LV wall thickness in multiple locations.
The frame rate should be sufficiently high (>40 Hz) to allow measure-
ment of the true end-diastolic wall thickness. Measurements of LV
wall thickness currently are made using 2D, M-mode or both, but the
2 techniques can yield different values for wall thickness and are not
interchangeable.16
If M-mode echocardiography is used, it is recommended that it be
guided by a 2D short-axis view (LOE low). With 2D echocardiography, it
is recommended that end-diastolic LV wall thicknesses be measured in at
least 2 right parasternal views (long axis and short axis), measuring the
thickest part of the septum and free wall in each view (LOE low). Using
2D-guided M-mode, it is recommended that septal and free wall thick-
nesses be measured using a leading edge-to-leading edge technique, so
that for the septum, the LV endocardial layer is excluded, and for the free
wall, the pericardium is excluded (LOE low).101 Using 2D echocardiogra-
phy, a leading edge-to-trailing edge technique should be considered for
measuring the septum, and a leading edge-to-leading edge technique
(excluding the pericardium) for measuring the LV free wall (LOE low). In
regions in which marked endocardial thickening occurs, it is rec-
ommended that the endocardial layer be excluded from the measure-
ments (LOE low). It is recommended that end-diastolic LV wall thickness
be measured from at least 3 cardiac cycles and averaged (LOE low). End-
diastolic and end-systolic LV diameters traditionally have been measured
using M-mode (using a leading edge-to-leading edge technique), but also
can be measured from 2D images (using a trailing-to-leading edge tech-
nique). Left ventricular fractional shortening is the most commonly used
quantitative index of LV systolic function, and regional wall motion
abnormalities usually are noted as a subjective finding. Papillary muscle
size and geometry are evaluated from right parasternal long and short
axis images and usually are described qualitatively, although they can be
quantitatively assessed.102
Left atrial size can be measured in short axis and long axis views.
Left atrial diameter can be measured in a right parasternal short-axis
view that includes the aortic valve cusps, and can be indexed to aortic
diameter (LA/Ao) in the same frame. Measurements can be made
either at end-systole103 or end-diastole.104 Reference intervals will
vary according to the timing within the cardiac cycle (LOE medium).
The LA diameter also can be measured in a right parasternal long-axis
4-chamber view at end-systole, from the interatrial septum to the LA
free wall (LOE medium).105 Left atrial fractional shortening is an index
of LA function, and can be measured using 2D-guided M-mode from
the same right parasternal short axis view as used for measurement of
LA/Ao.103 The presence of spontaneous echo-contrast (SEC) is associ-
ated with decreased LA function and blood stasis, and it is rec-
ommended that the LA appendage be evaluated in cats with LA
enlargement for the presence of SEC or thrombus106 and for evidence
of blood stasis using pulsed wave Doppler LA appendage flow veloci-
ties (LOE Low).
TABLE 4 Main indications for cardiac evaluation
History Syncope
Seizures (in the absence of other
neurological abnormalities)
Diagnosis of cardiomyopathy in a
close relative
Weakness
Exercise intolerance/open-mouth
breathing with exertion
Intolerance to parenteral fluid
administration
Pedigree cat intended for
breeding
Maine coon or Ragdoll with a
MyBPC3 mutation
Any endocrinopathy
Heartworm positive status
Fever of unknown origin
Physical exam Murmur
Gallop sound or systolic click
Muffled heart or lung sounds
Arrhythmia
Tachypnea
Pulmonary crackles
Jugular venous distention or
pulsation
Ascites
Hypo- or hyperkinetic femoral
arterial pulse pressure
Acute paresis/paralysis
Absent femoral arterial pulses
Cats aged 9 years or older
undergoing interventions
that could precipitate CHF
General anesthesia
Fluid treatment
Extended-release
glucocorticosteroids
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In addition to measuring cardiac chamber dimensions, it is rec-
ommended that the presence or absence of dynamic left ventricular
outflow tract obstruction (DLVOTO) be evaluated. Assessment of
DLVOTO can be made using a combination of 2D, M-mode, and
Doppler echocardiography. Careful imaging of the LVOT using 2D
echocardiography should allow identification of systolic anterior
motion of the mitral valve (SAM), where the septal leaflet of the mitral
valve is displaced towards the septum in systole, obstructing the
LVOT. Chordal anterior motion (CAM) also can be identified in the
same imaging view.107 Mitral valve SAM also can be imaged using M-
mode echocardiography. Color Doppler can be used to identify the
characteristic blood flow jets of LVOT obstruction and mitral regurgi-
tation, and spectral Doppler can be used to estimate the peak LVOT
gradient from left apical views (LOE Low). It is recommended that dia-
stolic function be assessed and a class of diastolic dysfunction
assigned using a combination of spectral Doppler and tissue Doppler
imaging (LOE medium).108,109 Table 5 summarizes recommended
echocardiographic protocols.
5.9.1 | Echocardiographic protocol for
cardiomyopathy screening in pedigree breeding cats
A standard-of-care scan should be undertaken at a minimum for
screening pedigree breeding cats. Such a scan consists of a quantita-
tive assessment of left heart chamber dimensions, including LA size,
LV wall thickness and LV diameter, as well as LA and LV fractional
shortening and a qualitative assessment of abnormal cardiac chamber
geometry and presence or absence of SAM of the mitral valve
(Table 5). No reference interval for maximal end-diastolic LV wall
thickness is universally accepted, and it is overly simplistic to expect a
single cutoff value for wall thickness to differentiate a normal ventri-
cle from a hypertrophied ventricle. Furthermore, wall thickness
increases with increasing body size,26,110,111 and is influenced by
hydration112,113 and heart rate.114 For the majority of normally-sized
cats, an end-diastolic LV wall thickness <5 mm is considered normal,
and ≧6 mm is indicative of hypertrophy. It is recommended that LV
wall thicknesses between 5 and 6 mm should be interpreted in the
TABLE 5 Echocardiographic protocols for a cat suspected of having cardiomyopathy according to level (basic to advanced)
Level of scan Measurements Qualitative assessment
Focused point-of-care Note presence of:
• Pleural, pericardial effusions
• Left atrial size & motion
• Pulmonary B-lines
• LV systolic function
Standard of care M-mode
• IVSd, LVFWd
• LVIDd, LVIDs, LV FS%
• LA FS%
2D
• IVSd, LVFWd
• LVIDd, LVIDs
• LA/Ao
• LA diameter from RP long axis view
Note presence of:
• Papillary muscle hypertrophy
• End-systolic LV cavity obliteration
• Papillary muscle/mitral leaflet abnormalities
• SAM or mid LV obstruction
• Dynamic RVOTO
• Abnormal cardiac chamber geometry
• Presence of spontaneous echo-contrast or thrombus
• Regional wall motion abnormalities
Best practice M-mode and 2D as for standard
of care, with the following
additional measurements:
Spectral Doppler
• Mitral inflow velocities
• Isovolumic relaxation time
• LVOT velocities
• RVOT velocities
• PVF velocities
• LAA blood flow velocities
Tissue Doppler imaging
• Lateral and septal mitral annular
velocities (pulsed wave Doppler mode).
Qualitative assessment as for standard of care
Note: “Focused point-of-care” scan: an abbreviated echocardiographic examination conducted because of patient instability, because the operator
has limited training in echocardiography, or both; “standard of care” scan: an echocardiographic examination that includes the content considered
to be standard by a trained, competent observer; “best practice” scan: an echocardiographic examination conducted by a cardiologist with
particular expertise in echocardiography. IVSd: end-diastolic interventricular septal thickness, LA: left atrial, LA FS%: left atrial fractional
shortening, LA/Ao: left atrial to aortic ratio at end-diastole and end-systole, or both, LAA: left atrial appendage, LV: left ventricular, LV FS%: left
ventricular fractional shortening, LVFWd: end-diastolic left ventricular free wall thickness, LVIDd: left ventricular internal dimension at end-
diastole, LVIDs: left ventricular internal dimension at end-systole, LVOT: left ventricular outflow tract, PVF: pulmonary venous flow, RP: right
parasternal, RVOT: right ventricular outflow tract, SAM: systolic anterior motion of the mitral valve.
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context of body size, family history, qualitative assessment of LA and
LV morphology and function, presence of DLVOTO and tissue Dopp-
ler imaging velocities. Where there is doubt, it is recommended that
the cat be classified as equivocal for LV hypertrophy and reevaluated
at a later date.
5.9.2 | Echocardiographic protocol for a cat
suspected to have cardiomyopathy
Further investigations are recommended when history, physical
examination findings, or both suggest that a cat might have cardiomy-
opathy (Table 4, LOE medium). Further investigations also should be
considered in older cats when anesthesia or treatment with IV fluid
therapy or extended-release corticosteroids is planned (LOE low). It is
recommended that a standard of care examination include a qualitative
evaluation of SEC and regional wall motion abnormalities (Table 5). A
best practice examination includes the above evaluations and Doppler
blood flow velocities recorded in the LVOT, across the mitral valve, in
the pulmonary veins, and in the LA appendage. Mitral annulus veloci-
ties also should be recorded with tissue Doppler imaging. If a standard-
of-care assessment is not possible, a focused point-of-care examination
still can provide some information on the presence of disease and risk
of CHF or ATE based on a qualitative assessment of LA size and cardiac
chamber geometry.
5.9.3 | Echocardiographic protocol for a cat
suspected to have congestive heart failure
For clinically unstable cats or where specialist level echocardiography
is not available, a focused point-of-care examination can be used to
identify the presence of pleural or pericardial fluid or both, presence
of B lines in lungs, and to provide a subjective estimate of LA size and
LV systolic function (Table 5).58 It is recommended that this examina-
tion be followed by a best practice examination or at least a standard-
of-care examination once the cat is more stable, using the protocol
suggested for cats with suspected cardiomyopathy.
5.10 | Approach to the diagnosis of subclinical
cardiomyopathy
Cats with subclinical cardiomyopathy can be difficult to identify. Car-
diac evaluation should be considered for cats with a suspicious history
or physical examination findings that include a gallop sound, murmur,
or arrhythmia, and in cats judged to be at high risk of CHF if subjected
to interventions such as anesthesia or IV fluid therapy (LOE low;
Table 4). Echocardiography is currently the most accurate clinical test
for diagnosis of cardiomyopathy in cats, and is also the best technique
for estimating prognosis, but is highly user-dependent.99 However,
with appropriate training and experience, focused point-of-care echo-
cardiography is feasible in first opinion (general) practice and can be
used to improve the accuracy of cardiomyopathy diagnosis by non-
specialist practitioners, particularly in cats with more advanced disease.42
It is recommended that focused point-of-care echocardiography be
undertaken only after appropriate training and practice42,99 (LOE high)
and a point-of-care examination should be followed at a later time point
with a standard echocardiographic examination to characterize the
phenotype.
When echocardiography is unavailable, evaluation of NT-proBNP
concentrations may be considered. Circulating NT-proBNP concentra-
tions increase with increasing clinical severity of cardiomyopathy in
groups of cats, but overlap precludes using NT-proBNP to categorize
individual cats into mild, moderate, and severe groups.69 The mea-
surement of NT-proBNP can be considered as an initial screening test
for identifying advanced cardiomyopathy. Normal NT-pro-BNP results
do not assure that a cat is free of cardiomyopathy, especially when
mild heart disease is present, nor do they guarantee that a cat will
remain free of cardiomyopathy later in life. They do however indicate
a low likelihood of cardiomyopathy that is immediately, clinically
harmful. Therefore, in a cat suspected of cardiomyopathy, follow-up
echocardiography still should be considered, even if initial NT-proBNP
results are within normal reference intervals (LOE low). It is rec-
ommended that a positive NT-proBNP test always be followed by an
echocardiographic examination.
In older cats with heart murmurs, gallop sounds or arrhythmias, it
is recommended that serum T4 concentration and blood pressure be
measured (LOE high). Echocardiography also should be considered
(LOE low).
5.11 | Approach to diagnosis in cats with
suspected CHF
Physical examination findings of tachypnea, labored breathing,
respiratory crackles, hypothermia, and a gallop sound are highly
suggestive of CHF,47 but in some cats tachypnea with labored
breathing might be the only abnormality detected. Although tho-
racic radiography traditionally has been considered the gold stan-
dard test for detecting cardiogenic pulmonary edema, care should
be taken to minimize stress when taking radiographs of cats with
respiratory distress. Pulmonary infiltrates and cardiomegaly are the
key findings with CHF, but classic radiographic features of CHF
such as LA enlargement and distended pulmonary vessels are
inconsistently identified in affected cats.52,54
If radiographs cannot be obtained safely, point-of-care thoracic
ultrasound examination or a point-of-care NT-proBNP test should be
considered (LOE high). With point-of-care ultrasound examination,
the presence of effusions or B-lines in association with severe LA
enlargement is highly suggestive of CHF.58,115 A negative result on a
point-of-care NT-proBNP test suggests that respiratory disease is
more likely to be the cause of respiratory distress than is cardiac dis-
ease. Once a cat with CHF has been stabilized, a standard-of-care or
best practice echocardiographic examination should be considered
(Table 5, LOE low).
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6 | TREATMENT
6.1 | Stage B1 cardiomyopathy
Treatment of cats with subclinical cardiomyopathy is controversial
because evidence is lacking. Although the majority of cats with stage
B1 cardiomyopathy will not develop clinical signs, it is recommended
that stage B1 cats be monitored annually for development of moder-
ate to severe LA enlargement (progression to stage B2). Cats with
stage B1 cardiomyopathy are considered at low risk of CHF or ATE,
and in general treatment is not recommended (LOE low).
There is no evidence that DLVOTO is associated with increased
morbidity or mortality in cats, and atenolol has not been shown to
have any effect on the 5-year survival rate in cats with subclinical
HCM.116 However, atenolol is expected to decrease DLVOTO gradi-
ent and heart rate,117 and may be considered in cats with stage B1
cardiomyopathy and severe DLVOTO, provided it can be administered
consistently (LOE low).
6.2 | Stage B2 cardiomyopathy
Cats with stage B2 HCM have an increased risk of developing CHF or
ATE. Primary prevention of ATE in cats with subclinical cardiomyopa-
thy has not been studied, but thromboprophylaxis is recommended
when known risk factors for ATE are present.11,106 Clopidogrel was
more effective than aspirin in cats that had survived a previous ATE
episode,118 and no other randomized, controlled studies have been
reported. Clopidogrel therefore is recommended in cats considered at
risk of ATE (moderate to severe LA enlargement, low LA FS%, low LA
appendage velocities, SEC; LOE medium). Clopidogrel does not elimi-
nate the risk of ATE, and thus other antithrombotic drugs can be con-
sidered in addition to clopidogrel in cats believed to be at very high
risk of ATE (eg, clopidogrel plus aspirin, clopidogrel plus a PO factor
Xa inhibitor, or clopidogrel plus aspirin plus a PO factor Xa inhibitor;
LOE low).
Cats with stage B2 cardiomyopathy should be monitored for pro-
gression of disease and development of clinical signs, but the effects
of stress caused by reexamination also should be taken into consider-
ation. If a stage B2 cat is reexamined, attention to appropriate han-
dling and minimizing stressful stimuli is important. If these measures
are (or are likely to be) insufficient, PO administration of appropriate
pharmaceuticals,119,120 synthetic feline pheromone application121-123
or both can be considered (LOE medium). Once the LA is moderately
to severely enlarged and antithrombotic treatment is started, manage-
ment is unlikely to change until clinical signs develop, but at a mini-
mum, it is recommended that owners monitor the cat's resting or
sleeping respiratory rate124 (LOE medium).
In 2 randomized, placebo-controlled studies, neither an angioten-
sin converting enzyme (ACE) inhibitor (ramipril) nor spironolactone
had any effect on LV mass or diastolic function in cats with subclinical
HCM, but study populations were small and limited to cats of a single
breed that had heritable cardiomyopathy.125,126 Similarly, benazepril
had no effect on time to treatment failure compared to placebo in a
randomized placebo-controlled study that included cats with subclini-
cal heart disease.127 No studies have been reported of pimobendan
use in cats with subclinical cardiomyopathy.
Ventricular ectopy is common in cats with HCM48,49and
ARVC48,128 and is associated with sudden death in people with these
cardiomyopathies.80,129,130 Treatment options in cats are limited, but
atenolol has been shown to decrease ventricular ectopy in cats with
HCM.117 It is recommended that cats with complex ventricular ectopy
be treated with atenolol (6.25 mg/cat q12h PO) or sotalol (10-20 mg/
cat q12h PO; LOE low). Markedly increased heart rate is observed in a
minority of cats with atrial fibrillation (AF),83 but AF occurs most often
in the setting of advanced cardiomyopathy where tachycardia is poorly
tolerated. Diltiazem, atenolol or sotalol may be considered in cats with
AF and a rapid ventricular response rate (LOE Low).
6.3 | Stage C
6.3.1 | Acute decompensated heart failure
Cats with pulmonary edema or pleural effusion caused by CHF usually
are presented with tachypnea and labored breathing. Empirical diuretic
treatment should be considered immediately when the index of suspicion
for CHF is high, for example, if hypothermia and a gallop sound are pre-
sent, especially when echocardiography or thoracic radiography is
unavailable or the risk of restraint for diagnostic evaluation appears to
exceed the benefits (LOE low). Supplementary oxygen administration is
recommended for any cat with respiratory distress, and sedation with an
anxiolytic (eg, butorphanol) also should be considered (LOE low). Stress
should be further minimized by gentle handling, a quiet environment, and
provision of a hiding box.131
Intravenous administration of furosemide, either as multiple boluses
of 1 to 2 mg/kg or a constant rate infusion, is recommended for CHF
and pulmonary edema in particular (LOE low). Thoracocentesis should be
performed when respiratory distress results from pleural effusion (LOE
low). Intravenous fluid treatment is contraindicated in cats with clinically
evident congestion, edema or effusion, and can exacerbate signs of CHF
even if diuretics are administered concurrently (LOE low). Ideally, mea-
suring blood chemistries can be considered before treatment if samples
can be obtained without compromising patient safety (LOE low), but
diuretic treatment is recommended for acute heart failure regardless of
the presence of azotemia (LOE low).
In cats with signs of low cardiac output (eg, hypotension, hypo-
thermia, bradycardia), PO treatment with pimobendan could be con-
sidered, provided DLVOTO is absent (LOE low). In cats with acute
heart failure and low cardiac output signs that do not show clinical
improvement after administration of pimobendan, a constant rate
infusion of dobutamine could be considered (LOE low). Evidence of
the efficacy of transdermal administration of nitroglycerin in cats is
lacking or conflicting, and its use is not recommended (LOE medium).
Angiotensin converting enzyme inhibition is not indicated during
acute decompensation of cats with cardiomyopathy (LOE low).
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Monitoring body temperature, respiratory rate, body weight, blood
pressure, and estimated urine output is recommended (LOE high).
Once stabilized, it is recommended that cats be discharged to the
care of their owners as soon as possible (LOE low). Reevaluation is
recommended 3-7 days after discharge to evaluate for resolution of
CHF and to evaluate renal function and serum electrolyte concentra-
tions (LOE low). It is recommended that owners monitor the cat's rest-
ing or sleeping respiratory rate with the goal of maintaining the
respiratory rate <30 breaths/min (LOE medium).
6.3.2 | Chronic heart failure
Furosemide is the primary drug used for control of pulmonary edema
and effusions in cats with CHF. Typically, treatment consists of furo-
semide 0.5 to 2 mg/kg PO q8-12 h, depending on the severity of clini-
cal signs of CHF. A common starting dosage is 1 to 2 mg/kg PO q12h
(LOE low). Intravenous administration is preferred in cats with marked
respiratory distress from pulmonary edema (see treatment of acute
decompensated heart failure, above). The maintenance dose of furose-
mide should be titrated to maintain a resting or sleeping respiratory rate at
home of <30 breaths/min (LOE low). Measurement of serum creatinine,
blood urea nitrogen, and electrolyte concentrations is recommended
3-7 days after initiating furosemide (LOE low). Angiotensin converting
enzyme inhibition with benazepril did not delay the onset of treatment
failure in a randomized, placebo-controlled study of cats with CHF127
(LOE high) although ACE inhibitors still are used by some cardiologists.
Prophylactic antithrombotic treatment with clopidogrel (18.75 mg/cat PO
q24h, with food) is recommended in any cat with a history of CHF and
moderate to severe LA enlargement (LOE low). Some cats react to
clopidogrel with salivation and retching or vomiting, which can be mini-
mized by administering the medication in an empty gelatin capsule,
followed by water. Pimobendan can be considered in cats without clini-
cally relevant LVOTO (LOE low).132 A commonly used dosage is 0.625 to
1.25 mg per cat q12h PO.
It is recommended that cats with stage C cardiomyopathy be
reexamined at approximately 2-4 month intervals or as needed. Consid-
eration should be given to the effects of stress caused by reexamination
on an individual basis. Owner-recorded resting or sleeping respiratory
rate can provide useful information for adjusting medication over the
phone without the need for clinic visits, although the presence of com-
orbidities and the risk of disease progression may necessitate periodic
reexaminations. For cats with a DCM phenotype, enquiries about dietary
history and measurement of plasma taurine concentrations are rec-
ommended, with supplementation and dietary change as necessary.
6.4 | Stage D (refractory)
Torsemide may be considered in place of furosemide in cats with per-
sistent CHF despite high doses of furosemide (>6 mg/kg/day PO), at a
starting dose of 0.1 to 0.2 mg/kg PO q24h and uptitrating to effect
(LOE low). Spironolactone 1 to 2 mg/kg PO q12h to q24h also can be
considered for management of chronic CHF.133 Adverse reactions (eg,
ulcerative dermatitis) have been reported in Maine Coon cats treated
with spironolactone at a dosage of 2 mg/kg q12h (LOE medium).126 In
cats with global LV systolic dysfunction, pimobendan is recommended
(LOE low).134 Taurine supplementation at 250 mg PO q12h also is rec-
ommended for cats with global LV systolic dysfunction unless plasma
taurine concentrations are in the normal range (LOE low).135 Foods
high in salt should be avoided (LOE low). As the number of medica-
tions increases, owner compliance is likely to decrease, and unneces-
sary medications should be avoided (LOE low).
Cardiac cachexia, defined as loss of muscle or lean body mass
associated with heart failure, may be present in cats with stage D car-
diomyopathy. Calorie intake should be prioritized over restriction of
sodium intake and body condition score should be recorded and an
accurate body weight obtained at every clinic visit (LOE low). It is rec-
ommended that serum potassium concentration be monitored and if
hypokalemia is identified, the diet should be supplemented with
potassium from either natural or commercial sources (LOE low).
6.5 | Management of ATE
Most cats with ATE presented to first opinion practice are eutha-
nized.136 This approach is justifiable In terms of the cat's welfare and
generally poor prognosis, but if analgesia is adequate and favorable
prognostic factors are present (eg, normothermia, only 1 limb
affected, absence of CHF),136,137 an attempt at treatment can be con-
sidered provided the owner is fully informed of the risks and overall
poor prognosis.
Analgesia is a priority for management of acute ATE in the first
24 hours, and treatment with a mu opioid agonist such as fentanyl,
hydromorphone, or methadone is recommended (LOE low). Anticoag-
ulant treatment is recommended using low-molecular-weight heparin
(LMWH) or unfractionated heparin, or a PO factor Xa inhibitor, which
should be started as soon as possible (LOE low). Thrombolytic treat-
ment is not recommended for cats with ATE (LOE high).138-140 If CHF
is present with ATE, management with furosemide and oxygen is rec-
ommended as necessary (LOE high), but it is important to note that
pain also can cause tachypnea, and this should not be mistaken for
the presence of CHF. It is recommended that clopidogrel be started as
soon as the cat can tolerate PO medications, with an initial loading
dose of 75 mg PO (LOE low) followed by 18.75 mg PO q24h (LOE
high). Heparin can be replaced by a PO factor Xa inhibitor in combina-
tion with clopidogrel (LOE low).
6.5.1 | Post-ATE
Reexamination is recommended 3-7 days after discharge from the
hospital, as well as 1-2 weeks after the ATE event. Evaluation should
include assessment of the distal limbs for evidence of necrosis, elec-
trolyte status, appetite, and treatment compliance, as well as the
degree of improvement in neuromuscular function. Resolution of
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lower motor neuron dysfunction can take weeks or months in some
cats,141 and reexamination should be considered every 1-3 months,
considering the effects of stress in the individual cat. It is rec-
ommended that the owner continue to monitor resting or sleeping
respiratory rate.
7 | CONCLUSIONS
Cardiomyopathies in cats are a heterogeneous group of myocardial disor-
ders of mostly unknown etiology and with potentially life-threatening
consequences. However, it is possible to identify cats at high risk of
adverse events. In this consensus statement, we have outlined an
approach to diagnosis and treatment that should be accessible to general
practitioners as well as specialists. We make several new recommenda-
tions: cardiomyopathy classification should be focused on phenotype,
but staging is more important for management than type of cardiomyop-
athy. Echocardiography is a very powerful tool that can provide valuable
information, but even a simple focused point-of-care ultrasound exami-
nation can be performed by nonspecialist practitioners to identify cats
at high risk of CHF or ATE, or those already presenting with CHF.
Evidence-based recommendations are provided on diagnosis and treat-
ment of cardiomyopathies according to stage.
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